December 2021, QureBio, invested and incubated by Viva BioInnovator, who is dedicated to the development of innovative antibody drugs, announced it has successfully completed nearly 200 Million RMB in Series B. The round was led by BOCOM International Holdings. Other investors who joined the round include Guoshun Investment, Oriza Holdings, Lihe Hongxin Venture Investment, Tianfu Sanjiang Capital, Spinnotec and Longmen Capital.